Integrating In Vitro Performance and In Vivo Patient-Reported Outcomes of a Mometasone Furoate Nasal Spray Device: A Translational Evaluation

Abstract

Background:

Intranasal corticosteroids (INCSs) are widely prescribed for allergic and nonallergic rhinitis and chronic rhinosinusitis, frequent causes of upper airway cough syndrome (UACS). In UACS, adherence is strongly influenced not only on pharmacological efficacy but also on device performance and sensory tolerability. Despite this, few studies have linked in vitro spray characteristics with patient-reported outcomes.

Objective:

To evaluate the technological characteristics and clinical acceptability of mometasone furoate administered via the liquid VP3 nasal spray device by integrating in vitro performance testing and in vivo patient-reported outcomes in individuals with chronic cough and UACS.

Methods:

In vitro experiments assessed deposition patterns in a silicone nasal cast, dripping behavior on inclined gel surfaces, viscosity, and spray plume geometry. An observational study enrolled 10 patients (80% female, mean age 56 ± 8.4 years) referred to a tertiary cough clinic for chronic cough (mean duration 3.5 years) associated with postnasal drip. Patients switched from conventional mometasone sprays to the device and completed Anchored Best–Worst Scaling evaluations of 11 sensory and treatment-related attributes. Global satisfaction was rated using a visual analog scale (VAS) and Treatment Satisfaction Index (TSI).

Results:

Deposition was reproducible (27.9 ± 1.7% of cast surface) with distribution into middle and lower turbinates. Moderate viscosity (14.4 ± 3.2 mPa·s) and stable plume geometry supported retention. In vivo, overall satisfaction scores remained stable following switching (TSI: 64.3 ± 3.4 vs 63.8 ± 4.6; VAS: 6.8 ± 3.2 vs 6.1 ± 1.6). However, patients reported significantly greater satisfaction in two sensory domains and rated three domains as more important (p < 0.05). No deterioration in any attribute was observed.

Conclusion:

The liquid VP3 nasal spray device delivering mometasone furoate demonstrated reliable in vitro performance and favorable patient acceptability in UACS. The correspondence between deposition behavior and patient-reported tolerability supports its suitability for INCS delivery and warrants further evaluation in larger, longer-term studies.

Keywords

mometasone furoate nasal spray patient-reported outcomes

Get full access to this article

View all access options for this article.

References

Bousquet

, Schünemann

, Togias

, et al.; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol, 2020; 145(1):70–80.e3; doi: 10.1016/j.jaci.2019.06.049

Fokkens

, Lund

, Hopkins

, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology, 2020; 58(Suppl S29):1–464; doi: 10.4193/Rhin20.600

Morice

, Millqvist

, Bieksiene

, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J, 2020; 55(1):1901136; doi: 10.1183/13993003.01136-2019

Baxter

, Myatt

, Stein

, et al. Spray pattern and plume geometry testing and methodology: An IPAC-RS working group overview. AAPS PharmSciTech, 2022; 23(5):145; doi: 10.1208/s12249-022-02278-w

Lobo

, Xi

, Das

, et al. Intranasal delivery: Formulation factors and insights into user experience. AAPS PharmSciTech, 2025; 26(6):179; doi: 10.1208/s12249-025-03171-y

May

, Dolen

. Evaluation of intranasal corticosteroid sensory attributes and patient preference for fluticasone furoate for the treatment of allergic rhinitis. Clin Ther, 2019; 41(8):1589–1596; doi: 10.1016/j.clinthera.2019.05.017

Fifer

, Toh

, Barkate

, et al. Patient satisfaction and sensory attributes of nasal spray treatments of olopatadine hydrochloride/mometasone furoate monohydrate and azelastine hydrochloride/fluticasone propionate for allergic rhinitis in Australia—An observational real-world clinical study. Patient Prefer Adherence, 2023; 17(0):141–151; doi: 10.2147/ppa.s389875

Williams

, Blatchford

, Mitchell

. In vitro anatomical models for nasal drug delivery. Pharmaceutics, 2022; 14(7):1353; doi: 10.3390/pharmaceutics14071353

Benninger

, Hadley

, Osguthorpe

, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg, 2004; 130(1):5–24; doi: 10.1016/S0194-5998(03)02085-0

10.

Patterlini

, Guareschi

, D’Angelo

, et al. Clinically relevant characterization and comparison of Ryaltris and other anti-allergic nasal sprays. Pharmaceutics, 2024; 16(8):989; doi: 10.3390/pharmaceutics16080989

11.

Kundoor

, Dalby

. Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm Res, 2010; 27(1):30–36; doi: 10.1007/s11095-009-0002-4

12.

Masiuk

, Kadakia

, Wang

. Development of a physiologically relevant dripping analytical method using simulated nasal mucus for nasal spray formulation analysis. J Pharm Anal, 2016; 6(5):283–291; doi: 10.1016/j.jpha.2016.05.003

13.

U.S. Food and Drug Administration. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Guidance for Industry. Silver Spring (MD): FDA; 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products

14.

U.S. Food and Drug Administration. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products: Chemistry, Manufacturing, and Controls Documentation. Guidance for Industry. Silver Spring (MD): Center for Drug Evaluation and Research (CDER), FDA; 2025. Available from: https://www.fda.gov/media/70877/download

15.

Osman

AMY

, Wu

, He

, et al. Eliciting SF-6Dv2 health state utilities using an anchored best-worst scaling technique. Soc Sci Med, 2021; 279:114018; doi: 10.1016/j.socscimed.2021.114018

16.

Djupesland

, Skretting

, Winderen

, et al. The importance of viscosity on nasal spray deposition and retention. Drug Deliv Transl Res, 2019; 9(1):140–148.

17.

Salade

, Wauthoz

, Goole

, et al. How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int J Pharm, 2019; 561:47–65; doi: 10.1016/j.ijpharm.2019.02.026

18.

Kundoor

, Dalby

. Effect of formulation- and device-related factors on nasal spray deposition. Adv Drug Deliv Rev, 2011; 63(7):901–908; doi: 10.1007/s11095-011-0417-6

19.

Meltzer

, Farrar

, Sennett

. Intranasal corticosteroid adherence: Patient perceptions of delivery systems. Allergy Asthma Proc, 2012; 33(Suppl 1):S40–S48; doi: 10.2500/aap.2012.33.3560

20.

Scadding

. Optimising intranasal corticosteroid therapy for allergic rhinitis. Allergy, 2012; 67(1):1–8; doi: 10.1111/j.1398-9995.2011.02725

21.

Price

, Scadding

, Ryan

, et al. The hidden burden of allergic rhinitis: Patient-reported outcomes with intranasal corticosteroids. Respir Med, 2014; 108(10):1445–1452; doi: 10.1016/j.rmed.2014.07.021

22.

Kimbell

, Frank

, Cannon

, et al. Deposition of intranasal spray drugs in a 3D printed nasal model. Respir Med, 2021; 176:106248; doi: 10.1016/j.rmed.2020.106248

23.

Djupesland

. Nasal drug delivery devices: Characteristics and performance in a clinical perspective. Allergy Asthma Proc, 2013; 34(2):213–219; doi: 10.2500/aap.2013.34.3633

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.02 MB

0.00 MB